---
title: "Innate Pharma S.A. (IPHA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/IPHA.US.md"
symbol: "IPHA.US"
name: "Innate Pharma S.A."
industry: "Biotechnology"
datetime: "2026-04-17T00:41:20.764Z"
locales:
  - [en](https://longbridge.com/en/quote/IPHA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/IPHA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/IPHA.US.md)
---

# Innate Pharma S.A. (IPHA.US)

## Company Overview

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.innate-pharma.com](https://www.innate-pharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-16T04:30:17.000Z

**Overall: D (0.75)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 284 / 393 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -52.08% |  |
| Net Profit YoY | -6.45% |  |
| P/B Ratio | -6.21 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 158354264.12 |  |
| Revenue | 10375701.14 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 764.21% | A |
| Profit Margin | -546.11% | E |
| Gross Margin | -384.40% | E |
| Revenue YoY | -52.08% | E |
| Net Profit YoY | -6.45% | C |
| Total Assets YoY | -36.23% | E |
| Net Assets YoY | -377.43% | E |
| Cash Flow Margin | 107.28% | B |
| OCF YoY | -52.08% | E |
| Turnover | 0.10 | E |
| Gearing Ratio | 134.61% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Innate Pharma S.A.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-52.08%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-6.45%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-6.21",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "158354264.12",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "10375701.14",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "764.21%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-546.11%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-384.40%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-52.08%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-6.45%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-36.23%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-377.43%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "107.28%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-52.08%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.10",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "134.61%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.79 | 289/393 | - | - | - |
| PB | -6.21 | 522/393 | 28.17 | 24.90 | 20.34 |
| PS (TTM) | 15.26 | 189/393 | 12.30 | 11.16 | 8.68 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 03 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 04 | Vertex Pharma (VRTX.US) | A | B | C | B | C | B |
| 05 | Regeneron Pharma (REGN.US) | A | C | C | B | C | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-07T04:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 75% |
| Hold | 1 | 25% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.62 |
| Highest Target | 8.00 |
| Lowest Target | 3.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/IPHA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/IPHA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/IPHA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/IPHA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**